To improve therapeutic strategies, we propose to dissect primary (intrinsic) resistance of a given melanoma to a panel of inhibitors with distinct modes of action. Our preliminary studies demonstrate that following a given drug treatment, melanoma cells not only enter apoptosis and necrosis, but they can also respond via one of two senescent phenotypes. These include either a """"""""natural"""""""" irreversible (terminal) senescence, or a second type of senescence that we have recently observed, which, while bearing the hallmarks of classical senescence, is reversible. Due to the fact that this reversible senescence can have tumor-protective properties and give rise to a proliferative population, we term it """"""""pseudo"""""""" senescence. This proposal is designed to define the role of therapy-induced senescence in melanoma and to develop novel therapeutic strategies that promote irreversible senescence and sensitize cells to therapy-induced apoptosis. In the first aim we will define therapy-induced senescence and will determine the molecular mechanisms underlying the heterogeneous responses to signaling modulators/inhibitors, including novel BRAF dimer inhibitors. It is likely that each type of senescence will have different outcomes, ranging from eventual cell death to the increase of invasion followed by re-growth. Our studies will assess the different cell fates to best define the mechanisms leading to the terminal senescence, and ultimately, cell death in combination with other reagents. In the second aim, we will develop therapeutic strategies for maximizing the induction of senescence/cell death in melanomas. We will test the hypothesis that pro-survival autophagy modulates the long-term responses to senescence induction and will develop combination therapies to induce irreversible senescence.
This proposal addresses the question why not all cancer cells within a tumor that are positive for the BRAF mutation are being killed. Besides dying when exposed to BRAF inhibitors, we have defined a senescence state, pseudo-senescence, where cells are just dormant and can recover to then grow again. We intend to molecularly dissect the two different senescence states and develop combination therapies that drive cells into irreversible senescence while disallowing cells to enter the pseudo-senescence state.
|Kaur, Amanpreet; Webster, Marie R; Marchbank, Katie et al. (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250-4|
|Budina-Kolomets, Anna; Webster, Marie R; Leu, Julia I-Ju et al. (2016) HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res 76:2720-30|
|Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24|
|Amaravadi, Ravi; Kimmelman, Alec C; White, Eileen (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913-30|
|Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :|
|Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol 11:2876-2888|
|Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3DÂ melanoma models. Pigment Cell Melanoma Res 29:317-28|
|Jennis, Matthew; Kung, Che-Pei; Basu, Subhasree et al. (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 30:918-30|
|Chatwichien, Jaruwan; Basu, Subhasree; Budina-Kolomets, Anna et al. (2016) PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric Î²-carboline. Bioorg Med Chem Lett 26:4884-4887|
|Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602|
Showing the most recent 10 out of 87 publications